Vettenranta A, Murtola TJ, Raitanen J, et al. - According to findings, use of statins does not materially compromise advantages of prostate-specific antigen (PSA)-based prostate cancer screening. PSA–based screening was found to be linked with less overdiagnosis of low-risk cancer in statin users, with similar mortality results as in nonusers.

• This is a post hoc subgroup analysis of a cohort of 78,606 men (median age, 59 years [range, 55-67 years]) in the Finnish Randomized Study of Prostate Cancer Screening, with statin purchase data available.

• Among statin nonusers, increased prostate cancer incidence in relation to PSA screening was evident (screening vs control, 11.2 vs 8.6 per 1000 person-years); rate ratio [RR], 1.31), but no similar elevation in incidence was noted in statin users (6.9 vs 5.9 per 1000 person-years; RR, 1.02).

• In statin users, a lower incidence of low-risk (Gleason score 6) and localized tumors was found, whereas detection of tumors with a Gleason score of 8 to 10 was similar.

• Irrespective of statin use, screening was related to a lower incidence of metastatic tumors.